Chargement en cours...
Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
The recent approval of molecular-targeted therapies for myeloproliferative neoplasm-associated myelofibrosis (MPN-MF) has dramatically changed its therapeutic landscape. Ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor, is now widely used for first- and second-line therapy in persons with MPN-MF,...
Enregistré dans:
| Publié dans: | Onco Targets Ther |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4445786/ https://ncbi.nlm.nih.gov/pubmed/26056473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S31916 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|